drugset
drugset / Trial / NCT06258174

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

NCT06258174 ↗

Phase 1 Completed 28 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will be collected. The study will last up to 65 days.

Timeline

Start
2021-09-28
Primary completion
2021-12-22
Completion
2021-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified 200 mg Oral

Indications

No indication recorded.